TriSalus Life Sciences, Inc. 8-K

What Happened
TriSalus Life Sciences, Inc. announced on January 12, 2026 that it issued a press release with preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025 and provided revenue guidance for 2026. The press release is attached to the company's Form 8-K as Exhibit 99.1.

Key Details

• Date filed: January 12, 2026 (Form 8-K).
• Scope: Preliminary, unaudited results for Q4 and year ended December 31, 2025, plus 2026 revenue guidance announced.
• Exhibit: Press release included as Exhibit 99.1 to the Form 8-K.
• Legal note: The announcement and Exhibit 99.1 are not being treated as “filed” under Section 18 of the Exchange Act and are not incorporated by reference in other filings.
• Signed by: David Patience, Chief Financial Officer.

Why It Matters
This filing gives investors an early, company-provided view of recent quarterly and annual earnings and a forward-looking revenue outlook for 2026. Because the figures are described as preliminary and unaudited, they may change when audited results are released; the legal note also limits certain liabilities and incorporation by reference. Investors should look for the full audited results and official earnings release for confirmed numbers and additional context.